These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 21073291

  • 1. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B, Schafer KR.
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [Abstract] [Full Text] [Related]

  • 2. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK, Triller DM, Yong CS, Lodise TP.
    Ann Pharmacother; 2004 Nov; 38(7-8):1226-35. PubMed ID: 15187209
    [Abstract] [Full Text] [Related]

  • 3. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS.
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [Abstract] [Full Text] [Related]

  • 4. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG.
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [Abstract] [Full Text] [Related]

  • 5. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
    Saravolatz LD, Leggett J.
    Clin Infect Dis; 2003 Nov 01; 37(9):1210-5. PubMed ID: 14557966
    [Abstract] [Full Text] [Related]

  • 6. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB.
    Curr Med Res Opin; 2007 Jun 01; 23(6):1403-13. PubMed ID: 17559736
    [Abstract] [Full Text] [Related]

  • 7. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
    Blondeau JM, Tillotson G.
    Int J Antimicrob Agents; 2008 Apr 01; 31(4):299-306. PubMed ID: 18276120
    [Abstract] [Full Text] [Related]

  • 8. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.
    Curr Med Res Opin; 2008 Mar 01; 24(3):895-906. PubMed ID: 18419876
    [Abstract] [Full Text] [Related]

  • 9. Gemifloxacin for community-acquired pneumonia.
    Lode HM, Schmidt-Ionas M, Stahlmann R.
    Expert Opin Investig Drugs; 2008 May 01; 17(5):779-86. PubMed ID: 18447602
    [Abstract] [Full Text] [Related]

  • 10. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M, Giménez MJ, Vicente D, Aguilar L, Pérez-Trallero E.
    Int J Antimicrob Agents; 2005 Feb 01; 25(2):163-7. PubMed ID: 15664487
    [Abstract] [Full Text] [Related]

  • 11. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.
    Clin Ther; 2008 Feb 01; 30(2):358-71. PubMed ID: 18343274
    [Abstract] [Full Text] [Related]

  • 12. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae.
    Owens RC, Bhavnani SM, Ambrose PG.
    Diagn Microbiol Infect Dis; 2005 Jan 01; 51(1):45-9. PubMed ID: 15629228
    [Abstract] [Full Text] [Related]

  • 13. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 14. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J, House HR, Siegel RE.
    Am J Med; 2005 Jul 01; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS.
    Int J Antimicrob Agents; 2004 Jun 01; 23(6):533-46. PubMed ID: 15194123
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, Moriya O, Kawanishi M, Kimura M, Matsushima T, Niki Y.
    J Infect Chemother; 2011 Oct 01; 17(5):678-85. PubMed ID: 21847518
    [Abstract] [Full Text] [Related]

  • 17. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
    Vallet CM, Marquez B, Ngabirano E, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
    Int J Antimicrob Agents; 2011 Sep 01; 38(3):249-56. PubMed ID: 21764262
    [Abstract] [Full Text] [Related]

  • 18. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L, Sevillano D, Martínez-Marín C, López-Casla MT, Gracia M, Alou L, del Carmen Ponte M, Prieto J, Soriano F, Spanish Pneumococcal Infection Study Network (G03/103).
    Int J Antimicrob Agents; 2006 Apr 01; 27(4):294-9. PubMed ID: 16527462
    [Abstract] [Full Text] [Related]

  • 19. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

  • 20. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
    Bhavnani SM, Andes DR.
    Pharmacotherapy; 2005 May 15; 25(5):717-40. PubMed ID: 15899734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.